BPI-23314: A novel orally bioavailable small molecular BET inhibitor with target protein degradation activity

被引：0
|
作者：
Guo, Jing [1 ]
Xu, Yan [1 ]
Yan, Dan [1 ]
Yu, Bo [1 ]
Yu, Weiwei [1 ]
Chen, Haibo [1 ]
Xu, Xiaofeng [1 ]
Liu, Xiangyong [1 ]
Lan, Hong [1 ]
Ding, Lieming [1 ]
Wang, Jiabing [1 ]
机构：
[1] Betta Pharmaceut Co LTD, Hangzhou, Peoples R China
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-1751
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1751
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
    Breit, Megan N.
    Kisseberth, William C.
    Bear, Misty D.
    Landesman, Yosef
    Kashyap, Trinayan
    McCauley, Dilara
    Kauffman, Michael G.
    Shacham, Sharon
    London, Cheryl A.
    BMC VETERINARY RESEARCH, 2014, 10
  • [32] In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease
    Patick, AK
    Brothers, MA
    Maldonado, F
    Binford, S
    Maldonado, O
    Fuhrman, S
    Petersen, A
    Smith, GJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) : 2267 - 2275
  • [33] Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines
    Megan N Breit
    William C Kisseberth
    Misty D Bear
    Yosef Landesman
    Trinayan Kashyap
    Dilara McCauley
    Michael G Kauffman
    Sharon Shacham
    Cheryl A London
    BMC Veterinary Research, 10
  • [34] Discovery and characterization of CX-4945 a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase 1 initiated
    Anderes, Kenna
    Siddiqui-Jain, Adam
    Streiner, Nicole
    Chua, Peter
    Pierre, Fabrice
    Omori, May
    Darjarnia, Levan
    Stansfield, Ryan
    Phung, Jennifer
    Bliesath, Josh
    Ho, Caroline
    Drygin, Denis
    O'Brien, Sean
    Rice, William
    CANCER RESEARCH, 2009, 69
  • [35] The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
    Baumann, Philipp
    Mandl-Weber, Sonia
    Oduncu, Fuat
    Schmidmaier, Ralf
    EXPERIMENTAL CELL RESEARCH, 2009, 315 (03) : 485 - 497
  • [36] Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
    Biftua, Tesfaye
    Scapin, Giovanna
    Singh, Suresh
    Feng, Dennis
    Becker, Joe W.
    Eiermann, George
    He, Hualbing
    Lyons, Kathy
    Patel, Sangita
    Petrov, Aleksandr
    Sinha-Roy, Ranabir
    Zhang, Bei
    Wu, Joseph
    Zhang, Xiaoping
    Doss, George A.
    Thornberry, Nancy A.
    Weber, Ann E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (12) : 3384 - 3387
  • [37] Antitumor Activity and Pharmacodynamic Biomarkers of a Novel and Orally Available Small-Molecule Antagonist of Inhibitor of Apoptosis Proteins
    Sumi, Hiroyuki
    Yabuki, Masato
    Iwai, Kenichi
    Morimoto, Megumi
    Hibino, Ryosuke
    Inazuka, Masakazu
    Hashimoto, Kentaro
    Kosugi, Yohei
    Aoyama, Kazunobu
    Yamamoto, Shunsuke
    Yoshimatsu, Mie
    Yamasaki, Hideki
    Tozawa, Ryuichi
    Ishikawa, Tomoyasu
    Yoshida, Sei
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (02) : 230 - 240
  • [38] Characterizing a novel "Minimalist Hybrid Protein" inhibitor designed to target Myc activity in cancer
    Hickman, K. Ashley
    Lustig, Lindsay C.
    Dingar, Dharmendra
    Ponzielli, Romina
    Bros, Christina
    Chan, Warren W. C.
    Shin, Jumi
    Penn, Linda J. Z.
    MOLECULAR CANCER RESEARCH, 2015, 13
  • [39] Novel selective orally bioavailable small molecule PAK4 allosteric modulators display antitumor activity and induce apoptosis in vitro and in vivo
    Senapedis, William
    Baloglu, Erkan
    Pursell, Natalie
    Crochiere, Marsha
    McCauley, Dilara
    Ellis, Joel
    Kashyap, Trinayan
    Klebanov, Boris
    Carlson, Robert
    Kalid, Ori
    Kauffman, Michael
    Shacham, Sharon
    Landesman, Yosef
    CANCER RESEARCH, 2014, 74 (19)
  • [40] YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models
    Xia, Yong
    Song, Xuejiao
    Li, Deliang
    Ye, Tinghong
    Xu, Youzhi
    Lin, Hongjun
    Meng, Nana
    Li, Guobo
    Deng, Senyi
    Zhang, Shuang
    Liu, Li
    Zhu, Yongxia
    Zeng, Jun
    Lei, Qian
    Pan, Youli
    Wei, Yuquan
    Zhao, Yinglan
    Yu, Luoting
    SCIENTIFIC REPORTS, 2014, 4
12345